Molecular Templates (MTEM) Competitors $0.16 -0.19 (-54.29%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends MTEM vs. AMGN, VRTX, GILD, REGN, ALNY, BIIB, UTHR, NBIX, INCY, and BMRNShould you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry. Molecular Templates vs. Amgen Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Amgen (NASDAQ:AMGN) and Molecular Templates (NASDAQ:MTEM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Which has more risk & volatility, AMGN or MTEM? Amgen has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Does the MarketBeat Community believe in AMGN or MTEM? Amgen received 1204 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 72.11% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote. CompanyUnderperformOutperformAmgenOutperform Votes154672.11% Underperform Votes59827.89% Molecular TemplatesOutperform Votes34267.32% Underperform Votes16632.68% Is AMGN or MTEM more profitable? Amgen has a net margin of 13.00% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 168.35% beat Molecular Templates' return on equity.Company Net Margins Return on Equity Return on Assets Amgen13.00% 168.35% 11.18% Molecular Templates -61.35%-260.50%-46.90% Do insiders and institutionals have more ownership in AMGN or MTEM? 76.5% of Amgen shares are held by institutional investors. Comparatively, 95.5% of Molecular Templates shares are held by institutional investors. 0.7% of Amgen shares are held by company insiders. Comparatively, 13.9% of Molecular Templates shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor AMGN or MTEM? In the previous week, Amgen had 8 more articles in the media than Molecular Templates. MarketBeat recorded 12 mentions for Amgen and 4 mentions for Molecular Templates. Amgen's average media sentiment score of 0.40 beat Molecular Templates' score of 0.37 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Molecular Templates 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend AMGN or MTEM? Amgen presently has a consensus target price of $319.67, suggesting a potential upside of 21.37%. Given Amgen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Amgen is more favorable than Molecular Templates.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.40Molecular Templates 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, AMGN or MTEM? Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$32.53B4.35$6.72B$7.8133.72Molecular Templates$23.48M0.04-$8.12M-$2.70-0.06 SummaryAmgen beats Molecular Templates on 16 of the 19 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Molecular Templates News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEM vs. The Competition Export to ExcelMetricMolecular TemplatesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.05M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.0610.5589.7417.16Price / Sales0.04196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book0.215.094.784.78Net Income-$8.12M$151.83M$120.31M$225.60M7 Day Performance-60.00%-2.14%-1.92%-1.23%1 Month Performance-52.28%-4.56%13.65%0.46%1 Year Performance-95.70%8.87%28.34%15.24% Molecular Templates Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEMMolecular Templates3.1833 of 5 stars$0.16-54.3%N/A-95.7%$1.05M$23.48M-0.0662News CoverageGap DownHigh Trading VolumeAMGNAmgen4.4684 of 5 stars$267.62-1.1%$319.68+19.5%-5.7%$143.85B$32.53B34.8626,700Analyst DowngradeGap UpVRTXVertex Pharmaceuticals4.7433 of 5 stars$465.61+0.4%$505.73+8.6%-0.8%$119.91B$9.87B-233.035,400Analyst ForecastAnalyst RevisionNews CoverageGILDGilead Sciences4.4784 of 5 stars$92.74+1.0%$96.43+4.0%+17.3%$115.58B$27.12B1,020.6718,000Insider TradeREGNRegeneron Pharmaceuticals4.6599 of 5 stars$728.42-0.4%$1,099.90+51.0%-16.6%$80.05B$13.12B18.1013,450Analyst ForecastALNYAlnylam Pharmaceuticals4.4122 of 5 stars$244.50-0.4%$298.09+21.9%+35.5%$31.54B$1.83B-93.682,100Analyst UpgradeBIIBBiogen4.6286 of 5 stars$150.33+0.2%$245.32+63.2%-42.3%$21.91B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.7048 of 5 stars$371.07+2.6%$370.86-0.1%+64.7%$16.57B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8286 of 5 stars$134.52+6.2%$165.00+22.7%+11.8%$13.62B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.7049 of 5 stars$70.41+2.7%$76.13+8.1%+11.6%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9845 of 5 stars$65.73-0.4%$94.20+43.3%-31.0%$12.53B$2.75B39.533,401Positive News Related Companies and Tools Related Companies AMGN Competitors VRTX Competitors GILD Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors NBIX Competitors INCY Competitors BMRN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MTEM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Templates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
